Asian Growth Companies With High Insider Ownership For May 2025
Top 10 Growth Companies With High Insider Ownership In Asia
Name
Insider Ownership
Earnings Growth
UTour Group (SZSE:002707)
23.5%
40.9%
M31 Technology (TPEX:6643)
30.8%
69.8%
Laopu Gold (SEHK:6181)
36.4%
40.2%
Global Tax Free (KOSDAQ:A204620)
20.8%
35.1%
Fulin Precision (SZSE:300432)
13.6%
44.2%
Oscotec (KOSDAQ:A039200)
21.1%
85.9%
Suzhou Sunmun Technology (SZSE:300522)
35.4%
77.7%
giftee (TSE:4449)
34.5%
67.1%
Vuno (KOSDAQ:A338220)
15.6%
148.2%
Techwing (KOSDAQ:A089030)
18.8%
65%
Click here to see the full list of 625 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.
Let's uncover some gems from our specialized screener.
Simply Wall St Growth Rating: ★★★★★★
Overview: ALTEOGEN Inc. is a biotechnology company that specializes in developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of approximately ₩18.99 trillion.
Operations: The company's revenue is primarily derived from its biotechnology segment, amounting to approximately ₩102.85 million.
Insider Ownership: 25.9%
ALTEOGEN demonstrates strong growth potential with earnings forecasted to grow 71.24% annually, significantly outpacing the Korean market's average. Revenue is also expected to increase by 54.9% per year, indicating robust expansion prospects. The stock is currently trading at a substantial discount of 50.8% below its estimated fair value, suggesting potential upside for investors. Despite high non-cash earnings, insider activity in recent months remains undisclosed, which may warrant further investigation for prospective investors.
KOSDAQ:A196170 Ownership Breakdown as at May 2025
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Chinasoft International Limited, along with its subsidiaries, offers IT solutions, IT outsourcing, and training services across several countries including China and the United States, with a market cap of approximately HK$13.37 billion.
Operations: The company's revenue is primarily derived from its Technology Professional Services Group, contributing CN¥14.77 billion, and its Internet Information Technology Services Group, which adds CN¥2.18 billion.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
What Canadian National Railway (TSX:CNR)'s Reduced Earnings Guidance Means For Shareholders
Earlier this month, Canadian National Railway faced ongoing operational challenges and reported that its expected business turnaround had not materialized, leading to reduced earnings growth guidance. This setback has sparked negative sentiment, with some industry observers drawing comparisons to competitors viewed as better positioned for growth and highlighting alternatives within the sector. With reduced earnings growth guidance in focus, we'll explore how these operational issues may shift Canadian National Railway's investment narrative. AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. Canadian National Railway Investment Narrative Recap To be a shareholder in Canadian National Railway, you need confidence in the company's ability to capitalize on long-term shifts toward intermodal and bulk transport as industries focus on supply chain resilience and North American trade. However, the recent reduction in earnings growth guidance directly impacts the key short-term catalyst, an expected business turnaround, and highlights concerns around volume growth, currently the most prominent risk for the business. The news meaningfully shifts investor attention from network advantages to near-term operational execution. Among recent announcements, the second-quarter results stand out. While CN grew net income and earnings per share compared to the prior year, sales have edged lower, reflecting the ongoing volume and demand pressures underpinning the news event. This reinforces the theme that even targeted capital spending and cost discipline will take time to translate into renewed growth, particularly if market conditions stay challenging. In contrast, investors should also be aware that structural shifts in customer routing and industry competitiveness could... Read the full narrative on Canadian National Railway (it's free!) Canadian National Railway's narrative projects CA$19.6 billion revenue and CA$5.6 billion earnings by 2028. This requires 4.6% yearly revenue growth and a CA$1.0 billion earnings increase from CA$4.6 billion today. Uncover how Canadian National Railway's forecasts yield a CA$153.14 fair value, a 19% upside to its current price. Exploring Other Perspectives Simply Wall St Community members provided 12 fair value estimates for CNR ranging from CA$119.59 to CA$170.64 per share. These divergent opinions come as growth in shipping volumes remains a critical uncertainty for the company's ability to regain momentum, explore the range of forecasts and viewpoints from across the Community. Explore 12 other fair value estimates on Canadian National Railway - why the stock might be worth 7% less than the current price! Build Your Own Canadian National Railway Narrative Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd. A great starting point for your Canadian National Railway research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision. Our free Canadian National Railway research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Canadian National Railway's overall financial health at a glance. Want Some Alternatives? Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay: Outshine the giants: these 19 early-stage AI stocks could fund your retirement. The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free. Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Asian Penny Stocks To Watch In August 2025
As global markets navigate a complex landscape of economic data and geopolitical developments, Asian stock markets are capturing attention with their unique opportunities. Despite the term "penny stocks" feeling somewhat outdated, these smaller or newer companies continue to offer intriguing investment prospects due to their affordability and potential for growth. In this article, we explore three penny stocks in Asia that stand out for their financial strength and ability to capitalize on current market conditions. Top 10 Penny Stocks In Asia Name Share Price Market Cap Financial Health Rating Food Moments (SET:FM) THB4.06 THB4.01B ★★★★★☆ Lever Style (SEHK:1346) HK$1.47 HK$909.23M ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.49 HK$2.07B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.645 SGD261.41M ★★★★★☆ China Sunsine Chemical Holdings (SGX:QES) SGD0.69 SGD657.83M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.91 SGD11.45B ★★★★★☆ Ekarat Engineering (SET:AKR) THB0.96 THB1.41B ★★★★★★ Livestock Improvement (NZSE:LIC) NZ$0.95 NZ$135.23M ★★★★★★ Rojana Industrial Park (SET:ROJNA) THB4.76 THB9.62B ★★★★★★ BRC Asia (SGX:BEC) SGD3.50 SGD960.23M ★★★★★★ Click here to see the full list of 971 stocks from our Asian Penny Stocks screener. We'll examine a selection from our screener results. Broncus Holding Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Broncus Holding Corporation is a medical device company specializing in interventional pulmonology products across Mainland China, the European Union, and internationally, with a market cap of HK$1.72 billion. Operations: The company's revenue is derived entirely from its medical products segment, totaling $8.13 million. Market Cap: HK$1.72B Broncus Holding Corporation, with a market cap of HK$1.72 billion and revenue of US$8.13 million, is navigating the volatile penny stock landscape with a focus on interventional pulmonology products. Despite being unprofitable, the company has reduced its losses by 27.8% annually over five years and maintains a strong cash position exceeding its debt. Recent approval for marketing its BroncAblate system in China marks a significant milestone, potentially enhancing revenue prospects through commercialization of this innovative lung cancer treatment device. While share price volatility remains high, short-term assets comfortably cover liabilities, providing financial stability amidst market fluctuations. Click here and access our complete financial health analysis report to understand the dynamics of Broncus Holding. Evaluate Broncus Holding's prospects by accessing our earnings growth report. Bosideng International Holdings Simply Wall St Financial Health Rating: ★★★★★★ Overview: Bosideng International Holdings Limited operates in the apparel business in the People's Republic of China, with a market cap of HK$55.11 billion. Operations: The company's revenue is primarily derived from Down Apparels at CN¥21.71 billion, followed by Original Equipment Manufacturing (OEM) Management at CN¥3.42 billion, Ladieswear Apparels at CN¥651.15 million, and Diversified Apparels at CN¥231.76 million. Market Cap: HK$55.11B Bosideng International Holdings, with a market cap of HK$55.11 billion, has shown solid financial performance in the apparel sector. The company reported annual sales of CN¥25.90 billion and net income of CN¥3.51 billion for the year ending March 31, 2025, reflecting growth from the previous year. Earnings per share also increased during this period. Bosideng's short-term assets exceed both its short- and long-term liabilities, indicating robust financial health. However, significant insider selling over the past quarter could raise concerns among investors despite stable earnings growth and seasoned management contributing to its operational stability in a volatile penny stock environment. Unlock comprehensive insights into our analysis of Bosideng International Holdings stock in this financial health report. Review our growth performance report to gain insights into Bosideng International Holdings' future. EVA Precision Industrial Holdings Simply Wall St Financial Health Rating: ★★★★★★ Overview: EVA Precision Industrial Holdings Limited is an investment holding company offering precision manufacturing services in China, Vietnam, and Mexico with a market capitalization of HK$1.54 billion. Operations: The company's revenue is primarily derived from two segments: Automotive Components, contributing HK$1.96 billion, and Office Automation Equipment, generating HK$4.34 billion. Market Cap: HK$1.54B EVA Precision Industrial Holdings, with a market cap of HK$1.54 billion, exhibits key strengths and challenges characteristic of penny stocks. The company's revenue is driven by its Automotive Components and Office Automation Equipment segments. Despite a low return on equity at 7.8%, EVA's interest payments are well covered by EBIT at 4.6 times, showcasing financial prudence. Its seasoned management team averages 32.6 years in tenure, contributing to operational stability amidst stable weekly volatility (4%). While the company has high-quality earnings and reduced debt levels over time, its dividend track record remains unstable, necessitating investor caution. Navigate through the intricacies of EVA Precision Industrial Holdings with our comprehensive balance sheet health report here. Gain insights into EVA Precision Industrial Holdings' outlook and expected performance with our report on the company's earnings estimates. Key Takeaways Click here to access our complete index of 971 Asian Penny Stocks. Seeking Other Investments? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:2216 SEHK:3998 and SEHK:838. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 hours ago
- Yahoo
Asian Market Insights: CNMC Goldmine Holdings And 2 Other Noteworthy Penny Stocks
As global markets respond to economic data and rate cut speculations, Asian indices have shown resilience amid these shifting dynamics. In this context, penny stocks—often representing smaller or newer companies—remain a relevant investment area despite their somewhat outdated label. By focusing on those with robust financials, investors can uncover potential opportunities for growth; here we examine CNMC Goldmine Holdings and two other noteworthy examples that may offer both stability and upside in the evolving market landscape. Top 10 Penny Stocks In Asia Name Share Price Market Cap Financial Health Rating Food Moments (SET:FM) THB4.06 THB4.01B ★★★★★☆ Lever Style (SEHK:1346) HK$1.47 HK$909.23M ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.49 HK$2.07B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.645 SGD261.41M ★★★★★☆ China Sunsine Chemical Holdings (SGX:QES) SGD0.69 SGD657.83M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.91 SGD11.45B ★★★★★☆ Ekarat Engineering (SET:AKR) THB0.96 THB1.41B ★★★★★★ Livestock Improvement (NZSE:LIC) NZ$0.95 NZ$135.23M ★★★★★★ Rojana Industrial Park (SET:ROJNA) THB4.76 THB9.62B ★★★★★★ BRC Asia (SGX:BEC) SGD3.50 SGD960.23M ★★★★★★ Click here to see the full list of 972 stocks from our Asian Penny Stocks screener. Let's uncover some gems from our specialized screener. CNMC Goldmine Holdings Simply Wall St Financial Health Rating: ★★★★★☆ Overview: CNMC Goldmine Holdings Limited is an investment holding company focused on the exploration and mining of gold deposits in Malaysia, with a market cap of SGD261.41 million. Operations: The company generates revenue primarily from its mining operations, totaling $88.33 million. Market Cap: SGD261.41M CNMC Goldmine Holdings has demonstrated robust financial performance, with earnings growing by 210.3% over the past year, significantly outpacing the industry. The company reported a net income of US$15.76 million for H1 2025, up from US$4.43 million the previous year, reflecting strong operational efficiency and high-quality earnings. Its short-term assets (US$51.3M) comfortably cover both short- and long-term liabilities, indicating solid financial health. Despite significant insider selling recently and an unstable dividend track record, CNMC's seasoned management team and favorable valuation compared to peers suggest potential for continued growth in this volatile sector. Click here to discover the nuances of CNMC Goldmine Holdings with our detailed analytical financial health report. Gain insights into CNMC Goldmine Holdings' future direction by reviewing our growth report. LifeTech Scientific Simply Wall St Financial Health Rating: ★★★★★★ Overview: LifeTech Scientific Corporation is an investment holding company that develops, manufactures, and trades interventional medical devices for cardiovascular and peripheral vascular diseases across Mainland China and other international markets, with a market cap of approximately HK$10.04 billion. Operations: The company's revenue is derived from three main segments: Structural Heart Diseases Business generating CN¥527.58 million, Peripheral Vascular Diseases Business contributing CN¥751.11 million, and Cardiac Pacing and Electrophysiology Business with CN¥25.01 million. Market Cap: HK$10B LifeTech Scientific Corporation, with a market cap of approximately HK$10.04 billion, operates debt-free and demonstrates financial stability by covering its short- and long-term liabilities with CN¥2.3 billion in short-term assets. However, the company faces challenges with negative earnings growth over the past year despite a 7.9% annual profit increase over five years. Its net profit margin has declined to 17.1% from 20.8%, reflecting pressures on profitability, while Return on Equity remains low at 4.8%. Recent board appointments may strengthen governance as LifeTech navigates industry competition amid stable volatility levels in its stock performance. Navigate through the intricacies of LifeTech Scientific with our comprehensive balance sheet health report here. Examine LifeTech Scientific's past performance report to understand how it has performed in prior years. SSY Group Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: SSY Group Limited is an investment holding company that engages in the research, development, manufacturing, trading, and sale of pharmaceutical products to hospitals and distributors both within the People's Republic of China and internationally, with a market cap of HK$9.06 billion. Operations: The company's revenue is primarily generated from its Intravenous Infusion Solution and Others segment, which accounts for HK$5.59 billion, followed by the Medical Materials segment with HK$405.07 million. Market Cap: HK$9.06B SSY Group Limited, with a market cap of HK$9.06 billion, primarily generates revenue from its Intravenous Infusion Solution segment. Recent approvals by China's National Medical Products Administration for drugs like Fampridine and Drotaverine Hydrochloride highlight the company's active pharmaceutical development strategy. Despite this, SSY faces challenges with negative earnings growth over the past year and a declining net profit margin to 18.4%. The company's financials show stability with short-term assets covering both short- and long-term liabilities, while interest payments are well covered by EBIT. However, dividend sustainability remains a concern due to limited free cash flow coverage. Take a closer look at SSY Group's potential here in our financial health report. Review our growth performance report to gain insights into SSY Group's future. Make It Happen Click this link to deep-dive into the 972 companies within our Asian Penny Stocks screener. Curious About Other Options? Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include Catalist:5TP SEHK:1302 and SEHK:2005. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
